| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, ... Science translational medicine 3 (75), 75ra26-75ra26, 2011 | 3650 | 2011 |
| Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ... Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017 | 1185 | 2017 |
| Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes H Zhuang, M Pourdehnad, ES Lambright, AJ Yamamoto, M Lanuti, P Li, ... Journal of Nuclear Medicine 42 (9), 1412-1417, 2001 | 798 | 2001 |
| NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 19 (3), 254-266, 2021 | 789 | 2021 |
| Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 20 (5), 497-530, 2022 | 718 | 2022 |
| NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines DS Ettinger, DE Wood, C Aggarwal, DL Aisner, W Akerley, JR Bauman, ... Journal of the National Comprehensive Cancer Network 17 (12), 1464-1472, 2019 | 670 | 2019 |
| NCCN guidelines insights: non–small cell lung cancer, version 5.2018 DS Ettinger, DL Aisner, DE Wood, W Akerley, J Bauman, JY Chang, ... Journal of the National Comprehensive Cancer Network 16 (7), 807-821, 2018 | 504 | 2018 |
| Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial CA Shu, JF Gainor, MM Awad, C Chiuzan, CM Grigg, A Pabani, ... The Lancet Oncology 21 (6), 786-795, 2020 | 484 | 2020 |
| Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ... Annals of Oncology 22 (12), 2616-2624, 2011 | 470 | 2011 |
| NCCN guidelines insights: non–small cell lung cancer, version 4.2016 DS Ettinger, DE Wood, W Akerley, LA Bazhenova, H Borghaei, ... Journal of the National Comprehensive Cancer Network 14 (3), 255-264, 2016 | 456 | 2016 |
| Non–small cell lung cancer, version 6.2015 DS Ettinger, DE Wood, W Akerley, LA Bazhenova, H Borghaei, ... Journal of the National Comprehensive Cancer Network 13 (5), 515-524, 2015 | 400 | 2015 |
| Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells BC Fuchs, T Fujii, JD Dorfman, JM Goodwin, AX Zhu, M Lanuti, ... Cancer research 68 (7), 2391-2399, 2008 | 396 | 2008 |
| Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma BC Fuchs, Y Hoshida, T Fujii, L Wei, S Yamada, GY Lauwers, CM McGinn, ... Hepatology 59 (4), 1577-1590, 2014 | 349 | 2014 |
| Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis KK Tanabe, A Lemoine, DM Finkelstein, H Kawasaki, T Fujii, RT Chung, ... Jama 299 (1), 53-60, 2008 | 255 | 2008 |
| Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor T Fujii, BC Fuchs, S Yamada, GY Lauwers, Y Kulu, JM Goodwin, M Lanuti, ... BMC gastroenterology 10, 1-11, 2010 | 231 | 2010 |
| Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma KL Molnar-Kimber, DH Sterman, M Chang, EH Kang, M ElBash, M Lanuti, ... Human gene therapy 9 (14), 2121-2133, 1998 | 229 | 1998 |
| Non–small cell lung cancer, version 1.2015 DS Ettinger, DE Wood, W Akerley, LA Bazhenova, H Borghaei, ... Journal of the National Comprehensive Cancer Network 12 (12), 1738-1761, 2014 | 222 | 2014 |
| SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor–mutant non–small-cell lung cancer NA Pennell, JW Neal, JE Chaft, CG Azzoli, PA Jänne, R Govindan, ... Journal of Clinical Oncology 37 (2), 97, 2019 | 205 | 2019 |
| Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition S Nakagawa, L Wei, WM Song, T Higashi, S Ghoshal, RS Kim, CB Bian, ... Cancer cell 30 (6), 879-890, 2016 | 186 | 2016 |
| Radiofrequency ablation for treatment of medically inoperable stage I non–small cell lung cancer M Lanuti, A Sharma, SR Digumarthy, CD Wright, DM Donahue, JC Wain, ... The Journal of thoracic and cardiovascular surgery 137 (1), 160-166, 2009 | 181 | 2009 |
Bryan C FuchsAssistant Professor of Surgery, Harvard Medical SchoolVerified email at mgh.harvard.edu
